|
Sex (male) – n (%) |
69 (48.94) |
101 (59.41) |
0.068 |
|
Age – median (IQR) (range)
|
65.7 (15.4) (50–92) |
64.5 (14.8) (50–90) |
0.585 |
|
Smoking status – n (%) |
| Smoker |
8 (5.67) |
24 (14.12) |
0.015
|
| Former smoker |
32 (22.70) |
28 (16.47) |
0.194 |
| Non-smoker |
101 (71.63) |
118 (69.41) |
0.709 |
|
BMI – n (%) |
| ≤29 |
101 (71.63) |
132 (77.65) |
0.239 |
| ≥30 |
40 (28.37) |
38 (22.35) |
0.239 |
|
SARS-CoV-2 serological status – n (%) |
| Antibody-positive |
70 (49.65) |
134 (78.82) |
<0.001
|
| Antibody-negative |
68 (48.23) |
35 (20.59) |
<0.001
|
| Other |
3 (2.13) |
1 (0.59) |
|
|
Anti-SARS-CoV-2 vaccination status – n (%) |
| 3 doses or 2 doses ≤120 days |
23 (16.31) |
66 (38.82) |
<0.001
|
| 1 or 2 doses ≥120 days or not vaccinated |
113 (80.14) |
99 (58.24) |
<0.001
|
| Other |
5 (3.55) |
5 (2.94) |
|
|
Comorbidities – n (%) |
| Diabetes |
3 (2.13) |
6 (3.53) |
0.519 |
| Cardiovascular disease |
56 (39.72) |
61 (35.88) |
0.557 |
| Chronic kidney disease |
7 (4.96) |
9 (5.29) |
1.000 |
| Chronic liver disease |
3 (2.13) |
12 (7.06) |
0.061 |
| Chronic pulmonary disease |
16 (11.35) |
33 (19.41) |
0.061 |
| Immunocompromising conditions |
17 (12.06) |
35 (20.59) |
0.048
|
|
Symptoms at enrolment – n (%) |
| Cough |
96 (68.09) |
118 (69.41) |
0.807 |
| Nasal congestion |
69 (48.94) |
69 (40.59) |
0.169 |
| Sore throat |
32 (22.70) |
69 (40.59) |
0.001
|
| Feeling hot or feverish |
103 (73.05) |
99 (58.24) |
0.008
|
| Myalgia |
46 (32.62) |
54 (31.76) |
0.903 |
| Fatigue |
47 (33.33) |
75 (44.12) |
0.062 |
| Headache |
59 (41.84) |
60 (35.29) |
0.244 |
| Anosmia/ageusia |
39 (27.66) |
4 (2.35) |
<0.001
|
| Nausea/vomiting |
28 (19.86) |
11 (6.47) |
<0.001
|
| Diarrhoea |
15 (10.64) |
12 (7.06) |
0.314 |
|
Serum C-reactive protein level – n
|
136 |
161 |
|
| Mean (SD), mg/L |
20.58 (29.00) |
14.29 (21.72) |
0.022
|
